Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01933035 · ClinicalTrials.gov registry record
Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.
A clinical trial, sponsored by Beth Israel Medical Center.
- Completed
- Registry status
- 50
- Enrollment target
NCT01933035 is a clinical trial that has completed, run by Beth Israel Medical Center. The registered enrollment target is 50 participants.
The verdict
NCT01933035 has completed, sponsored by Beth Israel Medical Center.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
Study Summary
To utilise extended platelet parameters in order to individuate Immune Thrombocytopenia (ITP) from hypo-proliferative causes of thrombocytopenia. To develop the clinical potential of the extended platelet parameters as they pertain to distinguishing different causes of thrombocytopenia from one another. To test the hypothesis that mean platelet component (MPC) and mean platelet mass (MPM) might distinguish between thrombocytopenia related to bone marrow dysfunction and immune mediated destruction of platelets.
Interventions
- OTHER Immune Thrombocytopenics
- OTHER Hypo-proliferative thrombocytopenics
- OTHER Control Population
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2013-10 |
| Est. Completion | 2015-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01933035
The ClinicalTrials.gov registry entry for NCT01933035 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Medical Center, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Immune Thrombocytopenics is the first listed.
NCT01933035 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01933035 about?
NCT01933035 is a clinical study titled "Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.". To utilise extended platelet parameters in order to individuate Immune Thrombocytopenia (ITP) from hypo-proliferative causes of thrombocytopenia. To develop the clinical potential of the extended platelet parameters as they pertain to distinguishing different causes of thrombocytopenia from one ano...
What is the current status of trial NCT01933035?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2013-10. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01933035?
The interventions under investigation include: Immune Thrombocytopenics (OTHER), Hypo-proliferative thrombocytopenics (OTHER), Control Population (OTHER).
Who is sponsoring clinical trial NCT01933035?
This trial is sponsored by Beth Israel Medical Center, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.